Araris Biotech
Basel, CH · 6 known investors
Find your way into Araris Biotech
171 people in our graph share verified history with the Araris Biotech team — schools, employers, funds. One of them is your warm intro.
Alex Mercandettiunlockedknows Dragan Grabulovski · together at ETH Zürich (overlapped)
×5knows the team · via ETH Zürich
×2knows the team · via Memo Therapeutics
×3knows the team · via Araris Biotech AG
knows the team · via Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson
Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy. The platform generates stable, homogenous ADCs for oncology applications without requiring antibody re-engineering.
Founders & leadership
DG
Dragan Grabulovskiin𝕏Co-founder and CEODragan Grabulovski is co-founder and CEO of Araris Biotech, which develops antibody-drug conjugate linker technology for targeted cancer therapy. He previously co-founded Covagen, which was sold to Johnson & Johnson in 2014.
PS
Philipp SpycherinCo-founder and Chief Scientific Officer
IA
Isabella Attinger-TollerinCo-founder
Investors · 6
In the news
Frequently asked questions
- What does Araris Biotech do?
- Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy. The platform generates stable, homogenous ADCs for oncology applications without requiring antibody re-engineering.
- Who founded Araris Biotech?
- Araris Biotech was founded by Dragan Grabulovski, Philipp Spycher, Isabella Attinger-Toller.
- Who are Araris Biotech's investors?
- Araris Biotech's investors include Pureos Bioventures, redalpine, Samsung Ventures, VI Partners, b2venture, Kinled Holding.
- Where is Araris Biotech headquartered?
- Araris Biotech is headquartered in Basel, CH.